News | May 16, 2022
Biological E. reduces Corbevax price to Rs.250 a dose
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Star Array's focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
The latest technology from ZEISS empowers surgeons with one complete, digitally integrated cataract workflow for efficiency without compromise
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Subscribe To Our Newsletter & Stay Updated
